Education
About Us
Working with TipRanks
Follow Us
Xenon Pharmaceuticals (XENE)
:XENE
XENE Stock Chart & Stats
$40.76
-$0.78(-1.91%)
At close: 4:00 PM EST
$40.76
-$0.78(-1.91%)
Day’s Range― - ―
52-Week Range$26.74 - $46.00
Previous CloseN/A
Volume41.45K
Average Volume (3M)786.42K
Market Cap
$3.14B
Enterprise Value$1.99B
Total Cash (Recent Filing)$487.55M
Total Debt (Recent Filing)$8.71M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Nov 05, 2025EPS Estimate
-1.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding77,105,800
10 Day Avg. Volume750,589
30 Day Avg. Volume786,417
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue198.92
Enterprise Value/Gross Profit267.19
Enterprise Value/Ebitda-6.30
Forecast
1Y Price Target
$55.59Price Target Upside36.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe enrollment completion of the Phase 3 X-TOLE2 study marks a key milestone for azetukalner.
Drug DevelopmentXenon aims to overcome limitations of earlier generation Kv7 openers and Nav1.7 inhibitors with potent, high free fraction and selective lead candidates.
EarningsThe company ended the quarter with approximately $625 million in cash, which management believes should fund operations into 2027.
Bears Say
CompetitionPotential competition from BioHaven Pharmaceuticals with its Kv7 channel modulator, BHV-7000, which is expected to readout results in focal onset epilepsy in 1H26.
Xenon News
XENE FAQ
What was Xenon Pharmaceuticals’s price range in the past 12 months?
Xenon Pharmaceuticals lowest stock price was $26.74 and its highest was $46.00 in the past 12 months.
What is Xenon Pharmaceuticals’s market cap?
Xenon Pharmaceuticals’s market cap is $3.14B.
When is Xenon Pharmaceuticals’s upcoming earnings report date?
Xenon Pharmaceuticals’s upcoming earnings report date is Nov 05, 2025 which is in 9 days.
How were Xenon Pharmaceuticals’s earnings last quarter?
Xenon Pharmaceuticals released its earnings results on Aug 11, 2025. The company reported -$1.07 earnings per share for the quarter, missing the consensus estimate of -$0.987 by -$0.083.
Is Xenon Pharmaceuticals overvalued?
According to Wall Street analysts Xenon Pharmaceuticals’s price is currently Undervalued.
Does Xenon Pharmaceuticals pay dividends?
Xenon Pharmaceuticals does not currently pay dividends.
What is Xenon Pharmaceuticals’s EPS estimate?
Xenon Pharmaceuticals’s EPS estimate is -1.15.
How many shares outstanding does Xenon Pharmaceuticals have?
Xenon Pharmaceuticals has 77,105,800 shares outstanding.
What happened to Xenon Pharmaceuticals’s price movement after its last earnings report?
Xenon Pharmaceuticals reported an EPS of -$1.07 in its last earnings report, missing expectations of -$0.987. Following the earnings report the stock price went up 5.512%.
Which hedge fund is a major shareholder of Xenon Pharmaceuticals?
Currently, no hedge funds are holding shares in XENE
Xenon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.59 (36.38% Upside)
$55.59 (36.38% Upside)
Blogger Sentiment
Bullish
XENE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 113.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.60%
12-Months-Change
Fundamentals
Return on Equity
-37.65%
Trailing 12-Months
Asset Growth
-23.72%
Trailing 12-Months
Company Description
Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
XENE Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Xenon Pharmaceuticals, with significant progress in their epilepsy and neuropsychiatric programs, strong financial health, and promising early-stage pipeline developments. However, there are some uncertainties in the bipolar depression program and regulatory filing timeline. Overall, the positive advancements strongly outweigh the noted uncertainties.View all XENE earnings summariesXENE Stock 12 Month Forecast
Average Price Target
$55.59
▲(36.38% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Scholar Rock Holding
―
Immunovant
―
Mineralys Therapeutics, Inc.
―
Ownership Overview
0.14% Insiders
29.43% Mutual Funds
0.10% Other Institutional Investors
64.21% Public Companies and
Individual Investors